Trial · NCT00884117
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Genotypic Resistance | Baseline (Day 1) and post-Baseline (Days 3, 6, 10) | All Laboratory-Confirmed Influenza Participants (ALCIP) Population: All with confirmed influenza by positive RT-PCR at Baseline. The Number of Participants Analyzed reflects the total of participants who provided evaluable data for their viral RNA subtype. The number who provided data for each viral RNA subtype in each timeframe (n) is shown. | participants | NUMBER |
| PRIMARY | Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) during Study Years 1, 2, 3, 4, 5, 6, 7 | ALCIP Population. The Number of Participants Analyzed reflects combined H3N2 or H1N1pdm09-infected participants across all study years who provided an analyzable post-Baseline sample for their viral RNA subtype. The number of participants who provided evaluable data for each viral RNA subtype in the specified timeframe (n) is shown in the table. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Adults Treated With Oseltamivir | Baseline (Day 1) | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Baseline visit. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Adults Treated With Oseltamivir | Day 3 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 3 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 3 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Adults Treated With Oseltamivir | Day 6 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 6 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 6 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Adults Treated With Oseltamivir | Day 10 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 10 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 10 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Children Treated With Oseltamivir | Baseline (Day 1) | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Baseline visit. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Children Treated With Oseltamivir | Day 3 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 3 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 3 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Children Treated With Oseltamivir | Day 6 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 6 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 6 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Children Treated With Oseltamivir | Day 10 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the Day 10 visit. The number of participants who provided evaluable data for each viral RNA subtype at the Day 10 visit (n) is shown in the table. | participants | NUMBER |
| SECONDARY | Time to Non-Detection of Viral RNA | From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) | ALCIP Population. The Number of Participants Analyzed reflects the number of participants who provided sufficient post-Baseline data. | days | MEDIAN |
| SECONDARY | Time to Non-Detection of Viral RNA Among Participants With H3N2 Infections | From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) | ALCIP Population. The Number of Participants Analyzed reflects the number of participants with H3N2 infection who provided sufficient post-Baseline data. | days | MEDIAN |
| SECONDARY | Time to Non-Detection of Viral RNA Among Participants With H1N1pdm09 Infections | From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) | ALCIP Population. The Number of Participants Analyzed reflects the number of participants with H1N1pdm09 infection who provided sufficient post-Baseline data. | days | MEDIAN |
| SECONDARY | Time to Non-Detection of Viral RNA Among Participants With Influenza B Infections | From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) | ALCIP Population. The Number of Participants Analyzed reflects the number of participants with influenza B infection who provided sufficient post-Baseline data. | days | MEDIAN |
| SECONDARY | Viral Load Among Adults Treated With Oseltamivir | Days 1, 3, 6, 10 | ALCIP Population. The Number of Participants Analyzed reflects the highest total number of participants who provided evaluable data for their viral RNA subtype at any visit. The number of participants who provided evaluable data for each viral RNA subtype at the specified visit (n) is shown in the table. | log10 vp/mL | MEAN |
| SECONDARY | Viral Load Among Children Treated With Oseltamivir | Days 1, 3, 6, 10 | ALCIP Population. The Number of Participants Analyzed reflects the highest total number of participants who provided evaluable data for their viral RNA subtype at any visit. The number of participants who provided evaluable data for each viral RNA subtype at the specified visit (n) is shown in the table. | log10 vp/mL | MEAN |
| SECONDARY | Percentage of Participants With Symptom Resolution on Day 6 Comparing Resistant and Susceptible Viruses | Day 6 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants with wild-type infection status at Baseline who provided evaluable data at the Day 6 visit. The number of participants who provided evaluable data for each resistance status at the Day 6 visit (n) is shown in the table. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants by Day of Viral RNA First Not Detected Comparing Resistant and Susceptible Viruses | Days 3, 6, 10 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants with wild-type infection status at Baseline who provided evaluable data at the specified visit. The number of participants who provided evaluable data for each resistance status at the specified visit (n) is shown in the table. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Resistant Versus Susceptible Viruses by Baseline Viral Load | Baseline (Day 1) | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants with wild-type infection status at Baseline who provided evaluable data. The number of participants who provided evaluable data for each resistance status at Baseline (n) is shown in the table. | percentage of participants | NUMBER |
| SECONDARY | Total Daily Symptom Score According to Global Assessment by the Investigator Among Adults Treated With Oseltamivir | Days 1, 6, 10 | ALCIP Population. The Number of Participants Analyzed reflects the total number of participants who provided evaluable data for their viral RNA subtype at the specified visit. The number of participants who provided evaluable data for each viral RNA subtype at the specified visit (n) is shown in the table. | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00884117/outcomes